Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 201

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Antibody–drug conjugates: in search of partners of choice

Open access
Fuentes-Antrás, Jesús, Genta, Sofia, Vijenthira, Abi, Siu, Lillian L. · 2023 · Trends in Cancer

Abstract

Antibody-drug conjugates (ADCs) have become a credentialled class of anticancer drugs for both solid and hematological malignancies, with regulatory approvals mainly as single agents. Despite extensive preclinical and clinical efforts to develop rational ADC-based combinations, to date only a limited number have demonstrated survival improvements over standard of care. The most appealing partners for ADCs are those that offer additive or synergistic effects on tumor cells or their microenvironment without unacceptable overlapping toxicities. Coadministration with antiangiogenic compounds, HER2-targeting drugs, DNA-damage response agents and immune checkpoint inhibitors (ICIs) represent active forerunners. Through the identification of targets with tumor-specific expression, improved conjugation technologies, and novel linkers and payloads offering superior therapeutic indices, the next generation of ADCs brings optimism to combinatorial approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.trecan.2023.01.003

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 94

  1. Tarantino, 2022, Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies, CA Cancer J. Clin., 72, 165
  2. Abrahams, 2019, Abstract NT-090: preclinical activity and safety of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometrial cancer, Clin. Cancer Res., 25, 10.1158/1557-3265.OVCASYMP18-NT-090 · doi:10.1158/1557-3265.ovcasymp18-nt-090
  3. Quanz, 2018, Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models, Oncotarget, 9, 34103, 10.18632/oncotarget.26135 · DOI
  4. Ponte, 2016, Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models, Neoplasia, 18, 775, 10.1016/j.neo.2016.11.002 · DOI
  5. Moore, 2018, Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer, Gynecol. Oncol., 151, 46, 10.1016/j.ygyno.2018.07.017 · DOI · Paper page
  6. O’Malley, 2020, Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer, Gynecol. Oncol., 157, 379, 10.1016/j.ygyno.2020.01.037 · DOI
  7. Bulat, 2018, Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, JCO, 36, 5571, 10.1200/JCO.2018.36.15_suppl.5571 · DOI
  8. Levy, 2022, MA13.07 TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC, J. Thorac. Oncol., 17, S91, 10.1016/j.jtho.2022.07.152 · DOI
  9. Janjigian, 2022, Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03, JCO, 40, 295, 10.1200/JCO.2022.40.4_suppl.295 · DOI
  10. Horwitz, 2022, The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma☆, Ann. Oncol., 33, 288, 10.1016/j.annonc.2021.12.002 · doi:10.1016/j.annonc.2021.12.002
  11. Tilly, 2022, Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma, N. Engl. J. Med., 386, 351, 10.1056/NEJMoa2115304 · DOI · Paper page
  12. Wahl, 2001, Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin, Int. J. Cancer, 93, 590, 10.1002/ijc.1364 · DOI
  13. Kan, 2015, Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells, BMC Cancer, 15, 726, 10.1186/s12885-015-1772-1 · DOI
  14. Beck, 2017, Strategies and challenges for the next generation of antibody–drug conjugates, Nat. Rev. Drug Discov., 16, 315, 10.1038/nrd.2016.268 · DOI · Paper page
  15. Martin, 2016, Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study, Ann. Oncol., 27, 1249, 10.1093/annonc/mdw157 · DOI
  16. Krop, 2016, Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer, Breast Cancer Res., 18, 34, 10.1186/s13058-016-0691-7 · DOI
  17. Moore, 2021, Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I, Ann. Oncol., 32, 757, 10.1016/j.annonc.2021.02.017 · DOI · Paper page
  18. Phillips, 2014, Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy, Clin. Cancer Res., 20, 456, 10.1158/1078-0432.CCR-13-0358 · DOI · Paper page
  19. Perez, 2017, Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the Phase III MARIANNE Study, J. Clin. Oncol., 35, 141, 10.1200/JCO.2016.67.4887 · DOI · Paper page
  20. Hurvitz, 2019, Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the Phase III KRISTINE Study, J. Clin. Oncol., 37, 2206, 10.1200/JCO.19.00882 · DOI · Paper page
  21. Krop, 2022, Trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab after anthracycline for high-risk human epidermal growth factor receptor 2-positive early breast cancer: the phase III KAITLIN Study, J. Clin. Oncol., 40, 438, 10.1200/JCO.21.00896 · DOI
  22. Lheureux, 2022, A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150, JCO, 40, 5514, 10.1200/JCO.2022.40.16_suppl.5514 · doi:10.1200/jco.2022.40.16_suppl.5514
  23. Patel, 2019, A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study), Breast Cancer Res., 21, 100, 10.1186/s13058-019-1186-0 · DOI
  24. Borges, 2018, Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial, JAMA Oncol., 4, 1214, 10.1001/jamaoncol.2018.1812 · DOI · Paper page
  25. Hurvitz, 2021, 126TiP HER2CLIMB-02: Tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer, Ann. Oncol., 32, S75, 10.1016/j.annonc.2021.03.140 · doi:10.1016/j.annonc.2021.03.140
  26. Krop, 2021, HER2CLIMB-04: phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress), JCO, 39, 10.1200/JCO.2021.39.15_suppl.TPS1097 · doi:10.1200/jco.2021.39.15_suppl.tps1097
  27. Haley, 2021, A phase I/Ib trial of PD 0332991 (palbociclib) and T-DM1 in HER2-positive advanced breast cancer after trastuzumab and taxane therapy, Clin. Breast Cancer, 21, 417, 10.1016/j.clbc.2021.03.005 · DOI
  28. Spring, 2021, Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer, NPJ Breast Cancer, 7, 103, 10.1038/s41523-021-00311-y · DOI
  29. Saatci, 2018, Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer, Oncogene, 37, 2251, 10.1038/s41388-017-0108-9 · DOI
  30. La Monica, 2017, Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines, J. Exp. Clin. Cancer Res., 36, 174, 10.1186/s13046-017-0653-7 · DOI
  31. Kayatani, 2020, Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations, Biochem. Biophys. Res. Commun., 532, 341, 10.1016/j.bbrc.2020.07.055 · DOI
  32. Scaltriti, 2009, Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity, Oncogene, 28, 803, 10.1038/onc.2008.432 · DOI · Paper page
  33. Collins, 2017, Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines, Cell. Immunol., 319, 35, 10.1016/j.cellimm.2017.07.005 · DOI
  34. O’Brien, 2022, Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer-targeted therapies, Mol. Cancer Ther., 21, 751, 10.1158/1535-7163.MCT-21-0847 · DOI
  35. Abraham, 2019, Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER2-positive breast cancer: NSABP Foundation Trial FB-10, J. Clin. Oncol., 37, 2601, 10.1200/JCO.19.00858 · DOI
  36. Kulukian, 2021, Abstract PS10-08: Tucatinib potentiates the activity of the antibody-drug conjugate T-DM1 in preclinical models of HER2-positive breast cancer, Cancer Res., 81, 10.1158/1538-7445.SABCS20-PS10-08 · doi:10.1158/1538-7445.sabcs20-ps10-08
  37. Pujade-Lauraine, 2014, Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial, J. Clin. Oncol., 32, 1302, 10.1200/JCO.2013.51.4489 · DOI · Paper page
  38. Chiorean, 2021, Randomized phase II study of PARP inhibitor ABT-888 (Veliparib) with modified FOLFIRI versus FOLFIRI as second-line treatment of metastatic pancreatic cancer: SWOG S1513, Clin. Cancer Res., 27, 6314, 10.1158/1078-0432.CCR-21-1789 · DOI
  39. Samol, 2012, Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study, Investig. New Drugs, 30, 1493, 10.1007/s10637-011-9682-9 · DOI · Paper page
  40. Yap, 2022, Phase Ib SEASTAR Study: combining rucaparib and sacituzumab govitecan in patients with cancer with or without mutations in homologous recombination repair genes, JCO Precis. Oncol., 6
  41. Cardillo, 2017, Synthetic lethality exploitation by an anti-trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer, Clin. Cancer Res., 23, 3405, 10.1158/1078-0432.CCR-16-2401 · DOI
  42. Yap, 2022, CT007 - PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations, Cancer Res., 82, CT007, 10.1158/1538-7445.AM2022-CT007 · DOI
  43. Nicolò, 2022, Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives, Cancer Treat. Rev., 106, 10.1016/j.ctrv.2022.102395 · DOI · Paper page
  44. D’Amico, 2019, A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer, J. Immunother. Cancer, 7, 16, 10.1186/s40425-018-0464-1 · DOI
  45. Müller, 2014, Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells, Cancer Immunol. Res., 2, 741, 10.1158/2326-6066.CIR-13-0198 · DOI · Paper page
  46. Iwata, 2018, A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model, Mol. Cancer Ther., 17, 1494, 10.1158/1535-7163.MCT-17-0749 · DOI · Paper page
  47. Boshuizen, 2021, Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade, Cancer Res., 81, 1775, 10.1158/0008-5472.CAN-20-0434 · DOI
  48. Rios-Doria, 2017, Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies, Cancer Res., 77, 2686, 10.1158/0008-5472.CAN-16-2854 · DOI
  49. Huang, 2022, A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2+tumors in hPD-1 transgenic mouse model and contributes immune memory formation, Breast Cancer Res. Treat., 191, 51, 10.1007/s10549-021-06384-4 · DOI
  50. Xia, 2021, HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells, Cell Chem. Biol., 28, 610, 10.1016/j.chembiol.2021.02.013 · doi:10.1016/j.chembiol.2021.02.013
  51. Emens, 2020, Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial, Lancet Oncol., 21, 1283, 10.1016/S1470-2045(20)30465-4 · DOI · Paper page
  52. Friedlander, 2021, Study EV-103: update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC), JCO, 39, 4528, 10.1200/JCO.2021.39.15_suppl.4528 · doi:10.1200/jco.2021.39.15_suppl.4528
  53. Sheng, 2022, JCO, 40, 4518, 10.1200/JCO.2022.40.16_suppl.4518 · doi:10.1200/jco.2022.40.16_suppl.4518
  54. Galsky, 2022, Primary analysis from DS8201-A-U105: a phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC), JCO, 40, 438, 10.1200/JCO.2022.40.6_suppl.438 · DOI
  55. Calvo, 2021, Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer, Cancer Treat. Res. Commun., 28
  56. Malhotra, 2021, A phase 1-2 study of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated extensive-stage SCLC, J. Thorac. Oncol., 16, 1559, 10.1016/j.jtho.2021.02.022 · DOI
  57. O’Malley, 2021, Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: final analysis, JCO, 39, 5504, 10.1200/JCO.2021.39.15_suppl.5504 · DOI
  58. Lorusso, 2022, Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205, JCO, 40, 5507, 10.1200/JCO.2022.40.16_suppl.5507 · doi:10.1200/jco.2022.40.16_suppl.5507
  59. Schmid, 2021, JCO, 39
  60. Boni, 2019, SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer, Metastatic Breast Cancer, 30
  61. Cheson, 2020, Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial, Lancet Haematol., 7, e808, 10.1016/S2352-3026(20)30275-1 · doi:10.1016/s2352-3026(20)30275-1
  62. Schmidt, 2022, Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): initial results from BEGONIA, a phase Ib/II study, Ann. Oncol., 33, S194
  63. Vergote, 2021, 723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study, Ann. Oncol., 32, S726, 10.1016/j.annonc.2021.08.1166 · doi:10.1016/j.annonc.2021.08.1166
  64. Zinzani, 2019, Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 Study, J. Clin. Oncol., 37, 3081, 10.1200/JCO.19.01492 · DOI · Paper page
  65. Advani, 2021, Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results, Blood, 138, 427, 10.1182/blood.2020009178 · doi:10.1182/blood.2020009178
  66. Skinner, 2017, Integrative analysis identifies a novel AXL-PI3 kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer, Clin. Cancer Res., 23, 2713, 10.1158/1078-0432.CCR-16-2586 · DOI
  67. Engelsen, 2022, Dissecting the role of AXL in cancer immune escape and resistance to immune checkpoint inhibition, Front. Immunol., 13, 10.3389/fimmu.2022.869676 · DOI
  68. Terry, 2019, AXL targeting overcomes human lung cancer cell resistance to NK- and CTL-mediated cytotoxicity, Cancer Immunol. Res., 7, 1789, 10.1158/2326-6066.CIR-18-0903 · DOI
  69. Hutchings, 2021, Glofitamab (Glofit) in combination with polatuzumab vedotin (pola): phase Ib/II preliminary data support manageable safety and encouraging efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), Blood, 138, 525, 10.1182/blood-2021-148359 · DOI
  70. Morschhauser, 2019, Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS), Lancet Haematol., 6, e254, 10.1016/S2352-3026(19)30026-2 · DOI · Paper page
  71. Liebers, 2021, Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas, Blood Adv., 5, 2707, 10.1182/bloodadvances.2020004155 · DOI
  72. de Oca, 2019, The anti-BCMA antibody-drug conjugate GSK2857916 drives immunogenic cell death and immune-mediated anti-tumor responses, and in combination with an OX40 agonist potentiates in vivo activity, HemaSphere, 3, 231, 10.1097/01.HS9.0000560524.63281.bc · DOI
  73. Callander, 2021, DREAMM-5 study: investigating the synergetic effects of belantamab mafodotin plus inducible T-cell co-stimulator agonist (aICOS) combination therapy in patients with relapsed/refractory multiple myeloma, Blood, 138, 897, 10.1182/blood-2021-152662 · doi:10.1182/blood-2021-152662
  74. Shekarian, 2017, Pattern recognition receptors: immune targets to enhance cancer immunotherapy, Ann. Oncol., 28, 1756, 10.1093/annonc/mdx179 · DOI · Paper page
  75. Amouzegar, 2021, STING agonists as cancer therapeutics, Cancers (Basel), 13, 2695, 10.3390/cancers13112695 · DOI · Paper page
  76. Harrison, 2007, Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans, J. Clin. Pharmacol., 47, 962, 10.1177/0091270007303766 · DOI
  77. Nuhn, 2018, Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses, Adv. Mater., 30, 10.1002/adma.201803397 · DOI · Paper page
  78. Ackerman, 2021, Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity, Nat. Cancer, 2, 18, 10.1038/s43018-020-00136-x · DOI · Paper page
  79. Blum, 2022, Abstract 2911: The CEA-targeted ISAC, BDC-2034, shows preclinical efficacy associated with innate immune activation, phagocytosis, and myeloid reprogramming, Cancer Res., 82, 2911, 10.1158/1538-7445.AM2022-2911 · DOI
  80. Kang, 2022, Abstract 5616: Tumor-targeted immune activation via a site-specific TLR7-agonist antibody-drug conjugate, Cancer Res., 82, 5616, 10.1158/1538-7445.AM2022-5616 · doi:10.1158/1538-7445.am2022-5616
  81. Kenkel, 2022, Abstract 4252: PD-L1-targeted ISAC combines myeloid cell activation, immune-checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models, Cancer Res., 82, 4252, 10.1158/1538-7445.AM2022-4252 · DOI
  82. Sharma, 2021, Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors, JCO, 39, 2549, 10.1200/JCO.2021.39.15_suppl.2549 · DOI
  83. Rodell, 2018, TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy, Nat. Biomed. Eng., 2, 578, 10.1038/s41551-018-0236-8 · DOI · Paper page
  84. Fu, 2015, STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade, Sci. Transl. Med., 7, 10.1126/scitranslmed.aaa4306 · DOI · Paper page
  85. Sato-Kaneko, 2017, Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer, JCI Insight, 2, 93397, 10.1172/jci.insight.93397 · DOI · Paper page
  86. Jin, 2020, Dual mechanisms of novel CD73-targeted antibody and antibody-drug conjugate in inhibiting lung tumor growth and promoting antitumor immune-effector function, Mol. Cancer Ther., 19, 2340, 10.1158/1535-7163.MCT-20-0076 · DOI
  87. Lupia, 2018, CD73 regulates stemness and epithelial-mesenchymal transition in ovarian cancer-initiating cells, Stem Cell Rep., 10, 1412, 10.1016/j.stemcr.2018.02.009 · DOI
  88. Turcotte, 2017, CD73 promotes resistance to HER2/ErbB2 antibody therapy, Cancer Res., 77, 5652, 10.1158/0008-5472.CAN-17-0707 · DOI
  89. Fabre, 2020, OMTX705, a novel FAP-targeting ADC demonstrates activity in chemotherapy and pembrolizumab-resistant solid tumor models, Clin. Cancer Res., 26, 3420, 10.1158/1078-0432.CCR-19-2238 · DOI
  90. Zammarchi, 2020, CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity, J. Immunother. Cancer, 8, 10.1136/jitc-2020-000860 · DOI
  91. Williams, 2020, Patient selection strategies to maximize therapeutic index of antibody-drug conjugates: prior approaches and future directions, Mol. Cancer Ther., 19, 1770, 10.1158/1535-7163.MCT-19-0993 · DOI
  92. Paller, 2014, Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee, Clin. Cancer Res., 20, 4210, 10.1158/1078-0432.CCR-14-0521 · DOI
  93. Cai, 2014, A Bayesian dose-finding design for oncology clinical trials of combinational biological agents, J. R. Stat. Soc. Ser. C Appl. Stat., 63, 159, 10.1111/rssc.12039 · doi:10.1111/rssc.12039
  94. Shah, 2021, The drug-dosing conundrum in oncology - when less is more, N. Engl. J. Med., 385, 1445, 10.1056/NEJMp2109826 · DOI · Paper page

Cited by

See all 201

Metadata

Authors
Fuentes-Antrás, J., Genta, S., Vijenthira, A., & Siu, L. L.
Venue
Trends in Cancer
Publisher
Elsevier BV
Published
2023-04
Volume
9
Issue
4
Pages
339-354
ISSN
  • 2405-8025 (ISSN-L)
  • 2405-8033
OpenAlex
W4319164392
Cited by
201
References
4
FWCI
11.32
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Conquer Cancer Foundation
  • University of Toronto

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibody–drug conjugates: in search of partners of choice. https://app.cochat.ai/papers/10.1016/j.trecan.2023.01.003
The paper
Fuentes-Antrás, J., Genta, S., Vijenthira, A., & Siu, L. L. (2023). Antibody–drug conjugates: in search of partners of choice. Trends in Cancer. https://doi.org/10.1016/j.trecan.2023.01.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.